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Heparin and heparinoids prevent the binding of immune complexes
containing nucleosomal antigens to the GBM and delay nephritis in
MRLIIpr mice. Monoclonal anti-nucleosome antibodies (mAbs) corn-
plexed to nucleosomal antigens can bind to DNA and to heparan sulfate
(HS) in ELISA and to the GBM in viva in a rat renal perfusion system,
whereas non-complexed mAbs do not bind [fl. In this study, we analyzed
whether heparin (HEP) or N-desulfated/acetylated heparins (DSA-HEP),
structurally and functionally strongly related to HS, are able to prevent the
binding of these complexed mAbs to DNA and to HS in vitro and to rat
GBM in viva. In ELISA the binding of nucleosome complexed anti-
nucleosome antibodies to DNA and HS was inhibited dose-dependently
by HEP, DSA-HEP and low molecular weight (LMW) DSA-HEP.
Intravenous injection of nucleosome/anti-nucleosome immune complexes
without heparin/hcparinoids in BALB/c mice led to GBM binding, while
simultaneous injection of heparin/heparinoids with complexed antibodies
or pretreatment with heparin subcutaneously prior to injection of com-
plexes prevented this binding. Subsequently, we tested the preventive
effect of HEP, DSA-HEP and LMW-DSA-HEP on progression of renal
disease in MRL/lpr mice. Treatment was started at an age of eight weeks
in a dose of 50 jg daily. With all three drugs albuminuria was significantly
delayed compared to PBS treated controls (cumulative incidence of
proteinuria at 20 weeks in controls 60% vs. 13%, 14% and 6% respectively
for HEP, DSA-HEP and LMW-DSA-HEP; P < 0.05). At week 21 the
glomerulonephritis was histologically less severe in heparin/heparinoid
treated animals (P = 0.02). In immunofluorescence the amount of
immunoglobulin and C3 deposits in the glomerular capillary wall tended
to be less in heparin/heparinoid treated mice compared to PBS treated
controls (P = 0.07). Furthermore, at 20 weeks anti-I-IS levels in plasma of
heparin/heparinoid treated mice were significantly lower (P < 0.05). We
conclude that interaction of heparin or heparin analogs with HS reactive
immune complexes containing nucleosomal antigens prevents the binding
of these immune complexes to the GBM and delays nephritis in MRL/lpr
mice.
Systemic lupus erythematosis (SLE) is an autoimmune disease
characterized by the occurrence of numerous autoantibodies,
primarily directed against nuclear antigens. Previously we have
shown that these anti-nuclear antibodies complexed to nucleoso-
mal antigens are able to bind to the glomerular basement
membrane (GBM) in viva [1, 2]. In these nucleosome containing
immune complexes the positively charged histones interact with
the negatively charged HS in the GBM [1]. The presence of these
nucleosomes in the complexes is also responsible for the binding
to heparan sulfate (HS) and DNA in vitro, since non-complexed
antibodies do not bind [1, 3]. In the present study, we investigated
whether heparin or heparin analogs, which have structurally and
functionally strong similarities with HS, could interfere with the
binding of these nucleosome complexed anti-nucleosome antibod-
ies to HS and DNA in vitro and to the GBM in vivo. Heparin is a
drug with many biological activities [4] and the therapeutic effects
of heparin in various experimental models of kidney diseases have
been investigated. In the renal ablation model heparin reduced
systemic blood pressure, proteinuria and the extent of glomerular
sclerosis [5—8]. Also in lupus mice heparin reduced the glomerular
damage [9]. In the puromycine aminonueleoside-induced ne-
phrotic syndrome, heparin treatment prevented glomerular scle-
rosis, mesangial proliferation and reduction of the glomerular
filtration rate [10]. The development of hypertension and fibrinoid
vascular lesions was prevented by heparin treatment in spontane-
ously hypertensive rats [11, 12]. In most studies a similar protec-
tive effect was also found for non-anticoagulant heparinoids [7,
10]. These results indicate that the beneficial effects can be
obtained without the risks of anti-coagulation. Because of the
renal protective properties and the functional and structural
similarities with HS, we analyzed the effects of heparin (HEP) and
the non-anticoagulant derivatives,
N-desulfated/acelylated heparin (DSA -HEP) and low molecular
weight N-desulfatedlaceiylated heparin (LMW-DSA-HEP) on
manifestatians of glomerulonephritis in a spontaneous model of
SLE, the MRL/lpr mouse
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We assessed the effects of heparin and of heparinoids on
autoantibody formation, proteinuria and glomerular Ig and com-
plement deposition in MRL/lpr mice both prophylactically as well
as therapeutically. In addition, we studied the effects of these
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drugs on the binding of complexed anti-nucleosomal autoantibod-
ies in ELISA to DNA and HS, and in vivo to the GBM.
Methods
Animals
MRL lpr/lpr mice were bred from stock originally obtained via
the Scripps Clinic and Research Foundation (La Jolla, CA, USA)
from the Jackson Laboratory (Bar Harbor, ME, USA). All strains
were maintained by brother/sister matings at our animal labora-
tory. For the in vivo inhibition studies, the in vivo coagulation
studies and the in vivo assessment of immune modulation by the
drugs, BALB/c mice were used, also originating from the Jackson
Laboratory.
Drugs
Heparin (HEP) was commercially obtained from Organon
Technica BV (Boxtel, The Netherlands). As non-coagulant hep-
arm derivatives DSA-HEP (KF-E4282) and LMW-DSA-HEP
(KF-E4567) were used, which were both produced and generously
provided by Diosynth BV (Oss, The Netherlands). The N-desul-
fation of heparin was carried out as described by Inoue and
Nagasawa [13]. Briefly, heparin was dissolved in water and passed
through a cation-column (Dowex 50W X 12) in the H-form. The
heparinic acid in the eluate was neutralized with pyridine (approx-
imately 2.5 ml per gram of heparin) to pH 6.5. After freeze-drying,
the pyridine salt of heparin was dissolved in 95% dimethylsul-
phoxide and 5% water and incubated for 30 minutes at 50°C. The
desulfated heparin was obtained by adsorption on an anion
exchanger (Bayer MP500A), elution with a 20% NaC1 solution
and precipitation with 75% methanol. Acetylation was carried out
as described by Hirano and Ohashi [14]. The N-desulfated
material was dissolved in a 10:1 water-methanol mixture and 1/20
of the total volume of acetic anhydride (1 ml per gram of heparin)
was added. The pH was kept constant by addition of a Dowex 1 X
8 ion exchanger in the carbonate form. DSA-HEP was obtained
by adsorption on an anion exchanger, elution, desalting on a G-l0
column and freeze drying. LMW-DSA-HEP was obtained by
enzymatic (heparin lyase 1, EC.4.2.2.7) digestion of HEP, which
then was desulfated and acetylated as described above. The
sulfate content was determined by conductometric titration as
described by Casu and Gennaro [15]. The N-acetyl content was
determined by proton-NMR as described by Casu [16]. For
control experiments a neutral polysaccharide Dextran (Pharma-
cia, Upsalla, Sweden) was used in concentrations identical to
those of heparin/heparinoids.
Anticoagulation studies
The anticoagulant properties of DSA-HEP and LMW-DSA-
HEP were analyzed and compared with standard HEP in vitro and
in vivo. The assay for anti-factor Xa activity was carried out as
described by Teicn et a! [17, 18] with minor modifications for use
in microtiter plates. In addition the effect of DSA-HEP, LMW-
DSA-HEP or HEP on the activated partial thromboplastin time
(aPTT) was determined by addition of the drugs to normal mouse
plasma in a concentration range of respectively 0 to 50 and 0 to 10
,ag/ml. For the in vivo effect groups of BALB/c and MRL/lpr mice
were treated for three days with daily subcutaneous injections of
0.1 ml saline or 50 jsg of either HEP, DSA-HEP or LMW-DSA-
HEP. Two hours after the last injection 0.9 ml blood was obtained
by cardiac puncture in a 1 ml syringe containing 0.1 ml of CTAD
solution (containing 0.089 si trisodium citrate, 0.021 M citic acid,
15 fLM theophyllin, 3.7 1aM adenosine and 0.198 sM dipyridamol).
The plasma was collected after centrifugation and aP'TT and
heparin levels were determined, according to Fischer [19]. Briefly,
in this assay 10 s1 CTAD plasma or standard sample were mixed
with 50 pA normal pooled plasma as a source of antithrombin III
and 150 jsl Tris-imidazole buffer (30 m in 0.25 M NaCI, pH 8.4)
and incubated for five minutes at 37°C. Thereafter 20 jsl thrombin
(6 U/ml) were added and the mixture was incubated for exactly 30
seconds. To measure the remaining free thrombin 20 pA (2 mM)of
the chromogenie substrate S 2238 (KabiVitrium) was added and
two minutes later the reaction was stopped with 50 pA 50% acetic
acid. The extinction at 450 nm was measured in a EAR 400
microplate reader (SLT, Groding, Austria). The heparin/AT
Ill-complex mediated anti-thrombin activity (= heparin level) was
calculated from a standard curve obtained with heparin. Treat-
ment of BALB/c and MRL/lpr mice with HEP resulted in heparin
levels of 6.0 3.0 and 3.1 1.5 mg/liter, respectively (controls
0.3 0.2 mg/liter). The aPTT was measured by mixing 100 pA of
citrated plasma with 100 pA PTT reagent of Stago (Asnières,
France) containing Kieselguractivator and cephalin. After incu-
bation for three minutes at 37°C, 100 pA 25 mrvi CaCl2 was added
and the clotting time was recorded with a KC 10 coagulometer
(Amelung, Germany).
Preparation of nucleosome complexed and purified
anti-nucleosome mAb
Anti-nucleosome antibodies are directed against nucleosome or
subnucleosomal complexes consisting of the histone octamer and
DNA. Purified non-complexed anti-nucleosome antibodies do not
bind to individual histones or DNA. However, complexed to
nucleosomal antigens these antibodies bind to DNA and HS in
ELISA and to the GBM in vivo [1]. Complexed antibodies of an
anti-nucleosomal antibody, mAb #34, were obtained by purifica-
tion of culture supernatant under physiological conditions as
described [1]. Noncomplexed mAb #34 was obtained by purifica-
tion under high salt conditions preceded by a DNase treatment as
previously described [1].
Antigen reactivity of purified and complexed anti-nucleosome mAb
and of plasma samples
Anti-DNA and anti-HS reactivities were determined in ELISA
as described previously [1, 20]. All ELISAs were titrated and the
reciprocal of the dilution giving an absorption of 1.0 at 450 nm was
used as titer.
Interaction of heparin or heparinoids with complexed
anti-nucleosome mAb
The in vitro effects of heparin/heparinoids were analyzed in an
inhibition ELISA to HS or DNA using a concentration range of
heparin, heparinoids or dextran. Fifty microliters of the different
inhibitors were added to the complexed anti-nucleosome mAb
#34. After incubation for 45 minutes at room temperature the
reactivity of the mAb to HS or DNA was measured in ELISA as
described before. In these inhibition experiments the mAb was
used in a concentration that gave 50% of the maximal absorption
in the respective direct ELISAs.
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The in vivo effects of heparin/heparinoids on GBM binding of
complexed mAb #34 were evaluated in two different ways: (1) by
renal perfusion studies in the rat of complexed mAb #34 with or
without hcparin; (2) by i.v. injection in BALB/c mice of complexed
mAb #34 with or without pretreatment of the mice with heparin.
For the renal perfusion studies male Wistar rats (150 g) were
anesthetized by intraperitoneal administration of 0.15 ml (9 mg)
sodium pentobarbital (Narcovet; Appharma, Arnhem, the Neth-
erlands). The control renal perfusion was performed as described
before [1]. For inhibition experiments 150 jig of complexed mAb
#34 was mixed with 150 jig of heparin/heparinoids for 30 minutes
at room temperature before renal perfusion. After perfusion the
perfused kidney was taken out and immediately snap frozen in
liquid N2 for evaluation of IgG binding by immunofluorescence
(IF).
The glomerular binding after i.v. injection of complexed mAb
was evaluated in BALB/c mice injected with 150 jig complexed
mAb #34 after pretreatment for three days with either daily
subcutaneous injections of 0.1 ml PBS or 50 jig HEP. Two hours
after the last injection, the complexed mAb #34 was injected i.v.
After five minutes the kidneys were taken out for IF.
Treatment protocols in MRL/Ipr mice
For the first set of experiments to test the preventive effect,
eight-week-old MRL/lpr mice were treated once daily with a
subcutaneous (s.c.) injection of 50 jig of either HEP, DSA-HEP
or LMW-DSA-HEP in 0.1 ml PBS. Control animals received 0.1
ml PBS s.c. daily. Each group consisted of 15 animals (8 males and
7 females). Mice were treated from week 8 until week 21. At the
start and after 12 weeks of treatment blood was drawn for the
determination of the anti-DNA and anti-HS titer in plasma.
Albuminuria was screened every week by urine collection in
metabolic cages for 18 hours. After 13 weeks of treatment (at the
age of 21 weeks) the animals were sacrificed and the kidneys were
removed for immunofluorescence.
In a second set of experiments, the therapeutic effect on
established albuminuria (albuminuria period before treatment <
7 days) was assessed. MRL/lpr mice between the ages of 20 to 30
weeks with an albuminuria of at least 1000 jig/18 hr were
randomized for magnitude of albuminuria, age and sex to treat-
ment with either 50 jig HEP, 50 jig LMW-DSA-HEP or 0.1 ml
PBS once daily subcutaneously (each group N = 12). After the
start of the treatment the albuminuria was analyzed every two
weeks and the effect on survival was evaluated. At several time
points during treatment plasma was collected for determination of
anti-DNA and anti-HS titers.
To investigate whether treatment with heparinoids could form
a useful addition to immunosuppressive treatment, we performed
a pilot experiment in which we tested whether the combination of
LMW-DSA-HEP and cyclophosphamide (CY) was more effective
than CY treatment alone. MRL//pr mice between the age of 20 to
25 weeks with an albuminuria of at least 300 jig/I 8 hr and a
duration of albuminuria of less than seven days, were randomized
for magnitude of albuminuria, age and sex. Mice were treated
once daily s.c. with either PBS (group A and group B) or with 50
jig LMW-DSA-HEP (group C). In addition mice in groups B and
C received a weekly i.p. injection of CY (EndoxanRAsta; Dagra
Pharma B.V., Diemen, The Netherlands) in a dose of 20 mg/kg
body wt while control mice in group A received an equivalent
volume of PBS. Each group consisted of 5 animals. The effect of
this treatment regimen was evaluated for albuminuria and sur-
vival.
Disease activity assessment
Anti-DNA and anti-HS reactivities were determined in ELISA
as described above. The HS ELISA was used to detect nucleo-
some complexed autoantibodies in the circulation [3]. After
collection of urine for 18 hours in metabolic cages, albuminuria
was analyzed with radial immunodiffusion with rabbit anti-mouse
albumin antibodies (Cappel, West Chester, PA, USA) as de-
scribed before [21, 22]. Mouse albumin 5 mg/mI (Sigma Chemical
Company, St. Louis, MO, USA) was used as a standard. To study
the glomerular deposition of mouse Ig and C3 and staining of
GBM HS, indirect immunofluorescence was performed on 2 jim
cryostat sections of kidney tissue, according to techniques de-
scribed previously [22]. The coded sections of the kidneys were
analyzed by 3 different observers and scored semiquantitatively on
a scale from 0 to 4+ (in at least 20 glomeruli per mouse kidney).
For staining of Ig and C3 both the amount and intensity of
staining was scored. No staining was scored 0; mild staining was
scored 1; moderate staining was scored 3 and severe staining was
scored 4. For HS staining in the capillary loops, no staining at all
was scored 0, staining of 25% off all capillary loops and/or 75%
decrease of staining intensity (as compared with a normal BALB/c
glomerulus) was scored 1; staining of 50% off all capillary loops
and/or 50% decrease of staining intensity was scored 2; staining of
75% of all capillary loops and/or 25% decrease of staining
intensity was scored 3, and normal staining of all capillary loops
was scored 4. For light microscopy tissue fragments fixed in
Bouin's solution were dehydrated and embedded in Paraplast
(Amstelstad B.V., Amsterdam, The Netherlands). Four-microme-
ter sections were stained with periodic acid-Schiff and silver
methenamine [21]. Coded sections were analyzed and scored on a
scale 0 to 3+. The 0 to 3+ scale was defined as follows: no
glomerulonephritis was scored 0; mild/moderate glomerulone-
phritis was scored I + to 2+; and severe glomerulonephritis was
scored 2+ to 3+.
In vivo assessment of immune modulating properties of
heparin/heparinoids
The immunosuppressive properties of HEP, DSA-HEP and
LMW-DSA-HEP were studied in normal BALB/c mice by mea-
suring their influence on delayed type hypersensitivity (DTH) and
primary antibody response towards bovine serum albumin (BSA)
according to methods described previously [23]. In brief, DTH
reactivity was determined in 4 groups of 10 BALB/c mice which
were treated daily with 0.1 ml PBS s.c. or 50 jig of either HEP,
DSA-HEP or LMW-DSA-HEP. Treatment was started at day —2.
At day (I all mice received 0.1 mg BSA in 0.1 ml complete
Freund's adjuvant s.c. At day 13 a rechallenge was given of 5 jil
BSA s.c. (2 mg/ml) into the pinna of the right ear. As control 5 jil
PBS was injected in the piona of the left ear. At 4, 24 and 48 hours
after the rechallenge duplicate measurements of the ear thickness
(x 10 3) were made with an engineer's micrometer. The DTI-I
reactivity is expressed as the ratio between the swelling of the
antigen injected site (R) and the saline injected Site (L) as
measured after 48 hours. At day 15 blood was collected from the
same animals for the determination of the anti-BSA response.
Anti-BSA titers were measured in ELISA [23]. During the whole
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Table 1. Biochemical characteristics and anti-coagulant properties of heparinoids and dextran used as a control non-charged polysaccharide
Drug Abbreviation
Number of
sulfate groups
per disaccharide
% Of glucosamine
residues containing
a N-acetyl group
Molecular
wt
Anti-Xa
activity
U/mg
aPIT
in viva
sec'
Heparin 1-IEP 3.0 25 15 kDa 200 39 12
N-desulfated/ acetylated heparin DSA-HEP 2.3 100 14 kDa <2.4 28 8
Low molecular weight LMW-DSA-HEP 2.3 100 7 kDa <2.4 25 5
N-desulfated/acetylated heparin
Dextran Dextran 0 ND 14 kDa <2.4 ND
Values are given as means SD. The aPTT in PBS treated animals was 30 6 sec. The values were statistically not different between drug and PBS
treated animals.
a The aPTI in mice treated once daily with a subcutaneous injection of 50 pg of either HEP, DSA-HEP or LMW-DSA-HEP compared to mice
treated with PBS (N = 5 per group)
experimental period the daily administration of the drugs was
continued.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney
U-test. A two-sided P < 0.05 was considered to be statistically
significant. Spearman's correlation coefficient was used for linear
regression analysis.
Results
Characteristics and anti-coagulant properties
The biochemical characteristics of HEP, DSA-HEP, LMW-
DSA-HEP and dextran are listed in Table 1. As can be seen only
HEP had an anti-factor Xa activity in vitro while the other
preparations were devoided of any anti-factor Xa activity. A
similar pattern was observed analyzing the effect on the activated
partial thromboplastin time (aPTT) in vitro. Even addition of
large amounts of DSA-HEP and LMW-DSA-HEP gave hardly
any prolongation of the aPTT (Fig. 1). To prolong the aPTT to
100 seconds 25 times more DSA-HEP than HEP was needed
while addition of LMW-DSA-HEP had no effect. The effect on
coagulation in viva using 50 rg of the various drugs is also shown
in Table 1. In all drug treated animals the aPTT was not
significantly different from control animals receiving PBS.
Inhibition of the binding of complexed anti-nucleosome mAb to
HS or DNA by heparin or heparinoids in ELISA
In pure non-complexed form mAb 34 reacted only with nucleo-
somes and had no reactivity with DNA or HS. Complexed with
nucleosomes, however, this mAb bound not only to nucleosomes
but also to DNA and HS as described before [11. The binding of
complexed mAb #34 to HS and DNA could be inhibited by HEP,
DSA-HEP and LMW-DSA-HEP in a dose-dependent manner as
shown in Figure 2. More DSA-HEP and LMW-DSA-HEP were
required to achieve a similar degree of inhibition as with heparin,
which in all probability is due to the partial desulfation of the
former reagents. In contrast to heparin and the heparinoids,
dextran was not able to inhibit the binding of complexed mAb #34
in these competitive inhibition ELISAs. This inhibition was not
unique for mAb #34 since HEP, DSA-HEP and LMW-DSA-HEP
could also inhibit to a similar degree the binding of other
previously described [1] complexed anti-nucleosome mAbs (#2
and #32) to HS and DNA (data not shown)
Inhibition of glomerular binding of complexed anti-nucleosome
mAb by heparin and heparinoids
Previously, we have shown that after renal perfusion of corn-
plexed anti-nucleosome mAb #34 glomerular binding occurs,
while in purified form the mAb does not show any binding [1]. In
this study, we tested the effect of heparin/heparinoids on this
GBM binding by renal perfusion (in Wistar rats) of complexed
mAb #34 with or without heparin/heparinoids (N = 3 per group).
When, prior to perfusion, complexed mAb #34 was mixed with
PBS clear binding of the complex to the glomerulus was seen.
After perfusion of complexed anti-nucleosome mAb #34 mixed
with dextran a comparable binding was observed (Fig. 3A).
However, the addition of heparin, DSA-HEP or LMW-DSA-HEP
to the complexed mAb #34 could completely prevent the glomer-
ular binding (Fig. 3B). Similar results were obtained after pre-
treatment of BALB/c mice with either PBS or HEP. BALB/c mice
were pretreated for three days with either daily s.c. injections of
PBS or HEP (N = 4 per group). Two hours after the last injection
the complexed mAb #34 was injected i.v. Pretreatment of the
mice with HEP resulted in detectable heparin levels (6.0 3.0
mg/liter; controls, 0.3 0.2 mg/liter) in the plasma at the time of
injection of the compexed anti-nucleosome mAb #34. When
complexed mAb #34 was injected i.v. after pretreatment with a
daily subcutaneous injection of PBS glomerular binding was
observed identical to that shown in Figure 3A. In contrast to this,
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Fig. 1. Effect of heparin (HEP; 0), N-desulfated/acetylated heparin (DSA-
HEP; S) or low molecular weight N-desulfated/acetylated heparin (LMW-
DSA-HEP; Lii) on aPTT in vitro.
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Fig. 2. Inhibition of the binding of the complexed anti-nucleosome mAb
#34 to HS (A) and DNA (B) in the inhibition ELISA. Binding of complexed
#34 was inhibited dose dependently by HEP (0), DSA-HEP (LII) and
LMW-DSA-HEP (•). Dextran (U) could not inhibit the binding. For
abbreviations see legend Figure 1.
i.v. injection of complexed mAb #34 in heparin pretreated mice
did not lead to any GBM binding.
Effects on glomerular disease in MRLIIpr mice
In the preventive study a daily dose 50 sg of HEP, DSA-HEP
or LMW-DSA-HEP significantly delayed the onset of albuminuria
in MRL/lpr mice compared to PBS treated controls (P < 0.05; Fig.
4). At 20 weeks the cumulative incidence of albuminuria in PBS
treated animals was 60%, while in the drug treated groups this was
respectively 13%, 14% and 6% for HEP, DSA-HEP and LMW-
DSA-HEP. Furthermore, the administration of HEP or hepari-
noids prevented the development of the histological hallmarks of
glomerulonephritis. At week 21, 10 out of 15 PBS treated control
MRL/lpr mice had glomerulonephritis. In contrast, mice treated
with HEP, DSA-HEP and LMW-DSA-HEP, respectively, showed
a significant lower prevalence of glomcrulonephritis (3/15, 3/14
and 2/15 of the mice, respectively, P 0.03, P = 0.03, P 0.008;
Fisher Exact test; Fig. 5). In direct immunotluorescence of kidney
sections of drug-treated animals we found compared with PBS
treated controls, that there was a decrease in the amount of
immunoglobulin deposits in the glomerular capillary wall (P =
0.07), but not in the mesangium (P = 0.90; Figs. 6 and 7 A, B).
The pattern of C3 deposition along the glomerular capillary wall
was identical to that of the Ig deposits. Less C3 deposits were
observed in heparin/heparinoid treated groups (Fig. 7 C, D).
Previously, we have shown that the staining of HS in the GBM of
MRL/lpr mice is significantly decreased and correlated with the
extent of IgG deposits [22]. In the present study we observed the
same phenomenon, since HS staining was markedly decreased in
the GBM of PBS treated mice compared with PBS treated
controls. However, in heparin/heparinoid treated mice this de-
crease in HS staining was much less as compared to PBS treated
controls (Fig. 7F). As we have described before [221 and also
found in this study, there was an inverse correlation between HS
staining and albuminuria (r =
—0.65, P < 0.0001) and GBM Ig
deposits (r. = —0.54, P < 0.0001). At the start of the treatment
the anti-DNA and anti-HS reactivities in plasma were similar in
all groups and rose with age (data not shown). After 12 weeks of
treatment the anti-HS levels were significantly lower in HEP,
DSA-HEP or LMW-DSA-HEP treated groups (P < 0.05, 0.03
and 0.05, respectively) compared to PBS treated controls (Fig. 8).
At that time there were no differences in anti-DNA antibody
levels between the groups. To establish whether HEP, DSA-HEP
and LMW-DSA-HEP could also exert an antiproteinuric effect in
MRL/lpr mice with an established albuminuria (range: 1000 to
9000 jxg/18 hr) animals were treated daily with 50 hg HEP or
LMW-DSA-HEP. In the PBS treated group there was an increase
of albuminuria in 90% of the mice. HEP and LMW-DSA-HEP
treated groups showed an increase of albuminuria in 55% and
60% of the mice, respectively. This difference was not statistically
significant. Both drugs also had no effect on survival, anti-DNA or
100 anti-HS titers (data not shown).
In the pilot experiment, in which the additive effect of heparin
to immunosuppressive treatment was tested, MRL/lpr mice with
an established albuminuria were treated with PBS/CY or LMW-
DSA-HEP/CY. Control mice were treated with PBS only. This
experiment revealed that there was a significant beneficial effect
on survival for the LMW-DSA-HEP/CY treated mice as com-
pared to PBS/CY treated mice (P < 0.05) and that the LMW-
DSA-HEP/CY treatment halted the progression of the protein-
uria.
Effects on immune reactivity
Treatment with 50 jig of either HEP, DSA-HEP or LMW-
DSA-HEP had no effect on DTH reactivity or on the primary
antibody response towards BSA (Table 2).
Discussion
This study shows that heparin and non-anticoagulant heparin
derivatives are able to inhibit the binding of nucleosome com-
plexed antibodies to DNA and HS. Also the in vivo GBM binding
of these complexes after renal perfusion was prevented. Further-
more, these drugs prevented the development of glomerular
lesions in MRL/lpr mice. In addition, we found that heparin/
heparinoid treatment can retard the onset of albuminuria and
significantly reduces anti-HS reactivity in plasma. Because hepa-
rin has many biological actions in inflammation and tissue repair
this beneficial effect could be due to number of actions. It has
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Fig. 3. Direct immunofluorescence of glomerulus after perfusion of complexed anti -nucleosome mAb #34 mired with dextran (A) or DSA-HEP (B). After
perfusion of complexed mAb #34 mixed with dextran clear binding of the complex to the glomerulus was observed (A). However, the addition of
DSA-HEP to the complexed mAb #34 could completely prevent this binding (B).
Fig. 4. Cumulative incidence of albuminuria in the various groups of
MRLIIpr mice. Starting at the age of eight weeks MRL//pr mice were
treated once daily with either 50 sg HEP, DSA-HEP or LMW-DSA-HEP
and compared with PBS treated controls. Each group consisted of 15
animals. Albuminuria was considered to be present if the urinary albumin
excretion exceeded 300 jrgIl 8 hr (upper limit of albuminuria (mean + 2 X
SD) in non-SLE normal control mice: 100 g/18 hr). PBS (•), HEP (•),
DSA-HEP () and LMW-DSA-HEP (0), P < 0.05.
been shown that heparin inhibits mesangial cell proliferation
[24—26], modulates protcoglycan synthesis in vitro [13, 26, 27] as
well as in vivo [10, 28, 29], exerts an anti-mitogenic effect on
glomerular epithclial cells [30] and inhibits the binding of immune
complexes to mesangial cells at least in vitro [31, 32]. From our
Fig. 5. Severity of glomerular lesions in MRL/lpr mice treated with PBS,
HEP, DSA-HEP or LMW-DSA-HEP. No glomerulonephritis (score 0, ),
mild glomerulonephritis (score <2+, ), severe glomeruloncphritis (score
>2+, LI).
data we cannot draw conclusions whether these properties con-
tributed to the anti-proteinuric observed effect, but there were no
differences between the control and drug treated mice in the
extent of mesangial matrix expansion and mesangial immunoglob-
ulin deposition. The beneficial effect of heparin could also be due
to its immunosuppressive properties [33—36]. However, it is
unlikely that this immunosuppressive effect is responsible for the
diminution of the glomerulonephritis, since no effect on primary
immune reactions like DTH and antibody response was evident.
Also, the fact that the levels of anti-DNA antibodies were
aI
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Fig. 6. The amount of Ig deposition in glomerular capillaiy loops () and
mesangium (El) in glomeruli of mice treated with PBS, HEP, DSA-HEP or
LMW-DSA-HEP. Deposition of Ig in the mesangium is similar in all
groups. A smaller amount of Ig deposition in the GBM was observed in
heparin/heparinoid treated mice compared to PBS treated controls.
unaltered does not provide support for an immunosuppressive
effect. Therefore, an alternative explanation for the renoprotec-
tive effect seems more likely. Several years ago we found that
anti-DNA antibodies could cross react with HS [3]. Later it
became apparent that this binding was not a direct antibody
binding but due to nucleosomes complexed to the antibody [2].
The histone part of the nucleosome was responsible for the
binding to HS. Based on these in vitro results we could show that
anti-nuclear antibodies complexed to nucleosomal antigens are
potential nephritogenic immune complexes via their interaction
with HS and other anionic sites in the GBM [1]. These complexes
can be identified in the circulation by using an anti-HS-ELISA [3].
This anti-HS reactivity correlates with the onset and exacerbation
of renal manifestations of SLE [37—39]. In this study we show that
heparin and heparinoids are able to prevent the binding of these
complexed anti-nucleosome antibodies to DNA and HS in
ELISA. In our view this inhibition is due to the binding of
heparin/heparinoids to cationic charged nucleosomal antigens
within the complex. This explanation is different from that offered
by others showing inhibition of binding of SLE auto-antibodies to
HS or DNA in ELISA by heparin [9, 40]. In these latter studies
inhibition of "direct" binding was suggested. That inhibition of
binding of nucleosome complexed anti-nuclear antibodies takes
place also in vivo is suggested by our finding that the plasma
anti-HS reactivity in the heparin/heparinoid treated mice was
significantly reduced. The inhibitory effect of heparin/heparinoids
is not restricted to serum-derived complexed autoantihodies but
also to antibodies eluted from glomeruli in SLE nephritis. In
glomerular eluates from albuminuric MRLIIpr mice, besides
strong anti-DNA reactivity, we also found anti-HS reactivity. Both
reactivities could be inhibited by heparin and heparinoids (van
Bruggen et al, unpublished observations). Similar results have
been published not only for MRL/lpr mice but also for human
SLE nephritis [91. These data support the suggestion that the
protective effect of heparin and heparinoids can be explained by
their ability to prevent the binding of nueleosome containing
immune complexes to HS in the GBM.
In line with the in vitro findings, we found in the acute GBM
binding studies that heparin/heparinoids were able to prevent
GBM binding both after renal perfusion and after i.v. injection of
nucleosome complexed antibodies. More importantly, a similar
mechanism seems to occur in the chronic model of lupus nephritis
in MRL/lpr mice. The onset of albuminuria was significantly
postponed by heparin and the used heparinoids. This was also
reflected by the decrease in histological severity of the glomeru-
lonephritis in the drug treated animals. Furthermore, the amount
of immunoglobulin deposits in the glomerular capillary wall
tended to be less in heparin/heparinoid treated MRL/lpr mice
compared to PBS treated controls. This decrease in IgG deposits
is relevant for the degree of proteinuria, since we found a strong
correlation between GBM-Ig deposits and albuminuria. Comple-
ment activation is an important contribution to tissue damage in
diseases mediated by immune complexes like lupus nephritis. The
pattern of C3 deposition along the capillary wall was identical to
the Ig deposition. This suggests that the reduced deposition of C3
in drug treated animals is secondary to the decrease of IgG
deposition. However, we cannot exclude that heparin and the
heparinoids had a direct effect on complement, since inhibition of
complement activation in vitro and in vivo has been described [41,
421.
In this study we could confirm in the control group our earlier
observation that in MRLIIpr mice the staining of GBM-HS is
strongly reduced and related to proteinuria and GBM-Ig deposi-
tion [22]. Heparin/heparinoids were able to prevent this decrease
of HS staining significantly. As outlined above, this seems to be
due to the reduction of deposition of nucleosome complexed
autoantibodies in the GBM. A similar mechanism has been
demonstrated for other cationic molecules like human platelet-
derived cationic molecules [31 and platelet factor 4 [44], which
binding to the glomerular polyanion was inhibited by heparin.
However, in recent years data has emerged that points to addi-
tional mechanisms which could explain the observed beneficial
effect of heparin. It was found that glycosaminoglycans (GAGs)
like heparin could prevent the progressive loss of HS-associated
anionic charges in the GBM in adriamycin nephropathy [45] and
in streptozotocin-induced diabetic nephropathy [46, 47]. The
significance of these observations is supported by our findings that
GBM-HS expression in adriamycin nephropathy [481 and diabetic
nephropathy [49] is significantly correlated to proteinuria. Indeed,
in patients with insulin-dependent diabetes microalbuminuria was
substantially reduced by heparin treatment [50]. These protective
effects were not related to the anticoagulant properties of the
agents. It is therefore conceivable that exogenous administration
of GAGs can interfere with the functional decrease of the
glomerular polyanion, that is, HS. A similar mechanism might
have contributed to the attenuation of the decreased expression of
HS in the GBM by heparin/heparinoids as observed in this study.
However, once albuminuria was established, heparin or heparin-
oid treatment did not reduce it, suggesting that the loss of HS was
not corrected anymore. We therefore assume that immune com-
plexes, once they are hound to the GBM, are not resolved by
heparin/heparinoids.
Our preliminary data on the combination treatment of LMW-
DSA-HEP and CY suggest that addition of non-anticoagulant
heparinoids to immunosuppressive drugs in the initial phases of
treatment of lupus nephritis could be of clinical importance. After
initiation of the immunosuppressive treatment for disease flares
the reduction of the autoantibody production is not immediate.
Fig. 7. Representative examples oft/ic immunofluorescence findings of glomeruli of MRL/lpr mice showing deposition of Ig after PBS treatment (A,) or IIEP
treatment (B); staining fbr C3 in PBS treated mice (C) and HEP treated mice (D); staining for HS in PBS treated mice (E) and HEP treated mice (F). The
few animals that developed albuminuria in the treated heparin/heparinoid treated groups showed a staining pattern similar to that of albuminuric PBS
treated controls.
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Fig. 8. The anti-HS reactivity at the age of 21 weeks in plasma samples of
MRL/lpr mice treated with PBS, HEP, DSA-HEP or LMW-DSA-HEP.
Individual titers are given plus the median value for each group. *p < 0.05.
Table 2. Influence of 50 rg daily of either HEP, DSA-HEP or LMW-
DSA-HEP on delayed type hypersensitivity (DTH) and primary
antibody response after immunization with BSA
Treatment DTH R/L ratio Primary antibody respons&'
PBS 1.5 0.2 100 (20—480)
HEP 1.4 0.2 80 (40 —320)
DSA-HEP 1.3 0.1 280 (10—640)
LMW-DSA-HEP 1.3 0.2 320 (10—1900)
During this period, temporary treatment with heparinoids could
prevent further glomerular damage by reducing the deposition of
nephritogenic complexes. Further studies are needed to see
whether this promising option is realistic.
In conclusion, our study indicates that heparin, and more
importantly non-coagulant heparin derivatives, are able to bind to
nephritogenic complexes consisting of nucleosomes and anti-
nuclear antibodies. This binding of heparin/heparinoids prevents
the subsequent deposition of these nephritogenic immune com-
plexes in the GBM. By this diminution of IgG deposition the
ensuing glomerular inflammation and albuminuria is reduced.
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